Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Updated interim phase IIa data demonstrate that the combination of simeprevir, odalasvir and AL-335 has a high level of efficacy in HCV patients

Posted on: 23 Sep 16
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that updated interim data from a phase IIa study being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies (Janssen), were presented on September 23rd at the European Association for the Study of the Liver (EASL) Special Conference in Paris, France. The updated results, which include expanded safety and efficacy data, were presented in the ePoster entitled "Short duration treatment with AL-335 and odalasvir (ODV), with or without simeprevir (SMV), in treatment naïve patients with hepatitis C virus (HCV) genotype (GT) 1 infection." The data show that 100 percent of patients receiving treatment for as short as six weeks with a triple combination of once-daily (QD) simeprevir 75mg and AL-335 800mg with 50mg every other day (QOD) of ODV achieved a sustained viral response 12 weeks after the completion of treatment (SVR12) as shown in the table below. +------+----------+---------+-----------+------------------+-------------------+ |Cohort|Simeprevir|Odalasvir|AL-335 dose|Treatment Duration| Number (%) with | |# | dose | dose | (mg) | (weeks) | SVR12 or SVR24 | | | (mg) | (mg) | | | | +------+----------+---------+-----------+------------------+-------------------+ |1 | 100 QD | 50 QD | 400 QD | 8 |20/20 (100%), SVR24| +------+----------+---------+-----------+------------------+-------------------+ |2 | -- | 50 QOD | 800 QD | 8 |18/20 (90%), SVR12 | +------+----------+---------+-----------+------------------+-------------------+ |3 | 75 QD | 50 QOD | 800 QD | 8 |20/20 (100%), SVR12| +------+----------+---------+-----------+------------------+-------------------+ |4 | 75 QD | 50 QOD | 800 QD | 6 |20/20 (100%), SVR12| +------+----------+---------+-----------+------------------+-------------------+ QD: every day; QOD: every other day; SVR: sustained virologic response. This study was designed to determine the safety, pharmacokinetics, and efficacy of different dosing regimens containing ODV and AL-335, with or without SMV, in treatment naïve patients with GT1 HCV infection for treatment durations of eight or six weeks. In all of these cohorts, the dosing regimens were generally well -tolerated. The majority of adverse events (AEs) were mild and the most commonly reported events were headache, fatigue, and upper respiratory tract infection. As previously reported in the abstract, there was one serious adverse event (SAE) in cohort 1 that resulted in premature discontinuation of all study drugs. This consisted of a Mobitz Type 1 2nd degree atrioventricular block and was deemed probably related to ODV and possibly related to AL-335 and simeprevir. The event was not associated with clinical or echocardiographic abnormalities, did not require any therapeutic intervention, resolved following treatment discontinuation, and the patient went on to achieve SVR24. No clinically significant laboratory, echocardiography, or ECG abnormalities (except the SAE) were reported. Selection of the triple combination for further development Based on the interim data from this study, the triple combination of simeprevir 75mg QD, odalasvir 25mg QD and AL-335 400mg QD has been selected for further development. The development program for the triple combination will include a multi-center, randomized, open-label study that will enroll treatment-naive and treatment-experienced non-cirrhotic patients chronically infected with hepatitis C virus genotypes 1, 2, 4, 5, and 6. In addition, the ongoing phase IIa study is assessing the triple combination in patients with or without compensated cirrhosis, and with HCV genotype 3 infection. Further information on these studies is available at with the reference numbers NCT02569710 and NCT02765490 For further information, please contact: Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580 Richard Bethell, CSO Medivir AB, mobile +46 (0)72 704 3211 Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 17.50 CET on 23rdSeptember 2016. About Medivir Medivir is a research based pharmaceutical company with a research focus on oncology and infectious diseases. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.GlobeNewswire

Last updated on: 26/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.